Finance

Lists
LXEO:NASDAQ
Lexeo Therapeutics Inc
US$ ३.०७
+०.३३%
(+०.०१००) 1D
US$ ३.०७
०.००% (०.००)
After hours
Closed: नोभेम्बर ११, १६:००:०१ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LXEO...
Open
US$ ३.०९
High
US$ ३.२१
Low
US$ ३.०४
Mkt. cap
२५.२० करोड
Avg. vol.
१५.४१ लाख
Volume
०.००
52-wk high
US$ १०.९९
52-wk low
US$ २.५५
EPS
-US$ १.१६
Shares outstanding
८.२१ करोड
No. of employees
६३
Open
US$ ३.०९
High
US$ ३.२१
Low
US$ ३.०४
Mkt. cap
२५.२० करोड
Avg. vol.
१५.४१ लाख
Volume
०.००
52-wk high
US$ १०.९९
52-wk low
US$ २.५५
EPS
-US$ १.१६
Shares outstanding
८.२१ करोड
No. of employees
६३
News stories
From web sources and news partners
About Lexeo Therapeutics Inc
CEO-
Employees६३
Founded२०१७
Headquarters-
SectorHealth Care
Industry-
Websitelexeotx.com
Analyst ratings
Based on 4 analysts giving stock ratings to LXEO in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for LXEO in the last 3 months.
Highest
Current US$ ३.०७
US$ २३.०० (+६४९.१९%)
Average
US$ १८.७५ (+५१०.७५%)
Lowest
US$ १५.०० (+३८८.६०%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
US$ २३.००
+६४९.२%
10/21/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
US$ १७.००
+४५३.७%
10/05/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
US$ १५.००
+३८८.६%
09/23/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
US$ २०.००
+५५१.५%
09/23/2026
Luca Issi
RBC Capital
Buy
Maintained
US$ २०.००
+५५१.५%
08/12/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
US$ ९.००
+१९३.२%
06/25/2026
Unknown Analyst
Stifel Nicolaus
Buy
Maintained
US$ १७.००
+४५३.७%
05/12/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
US$ १७.००
+४५३.७%
05/11/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
US$ १०.००
+२२५.७%
01/13/2026
Christopher Raymond
Raymond James
Buy
Maintained
US$ २५.००
+७१४.३%
01/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
१.५७ करोड
१.६२ करोड
१.५७ करोड
१.९० करोड
Cost of revenue
१.५७ करोड
१.६२ करोड
१.५७ करोड
१.९० करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५९.५३ लाख
६९.०६ लाख
६६.३० लाख
८९.९३ लाख
Operating expense
५९.५३ लाख
६९.०६ लाख
६६.३० लाख
८९.९३ लाख
Total operating expenses
२.१६ करोड
२.३१ करोड
२.२३ करोड
२.८० करोड
Operating income
-२.१६ करोड
-२.३१ करोड
-२.२३ करोड
-२.८० करोड
Other non operating income
-९.०० हजार
९.०० हजार
-१.०० हजार
-६.०० हजार
EBT including unusual items
-२.०३ करोड
-२.०९ करोड
-२.०२ करोड
-२.५९ करोड
EBT excluding unusual items
-२.०२ करोड
-२.०९ करोड
-२.०२ करोड
-२.५८ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-२.०३ करोड
-२.०९ करोड
-२.०२ करोड
-२.५९ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.३३
-०.२७
-०.२५
-०.३०
Interest and investment income
१४.५६ लाख
२२.१३ लाख
२१.१३ लाख
२१.९४ लाख
Interest expense
-२२.०० हजार
-२०.०० हजार
-१७.०० हजार
-१४.०० हजार
Net interest expenses
१४.३४ लाख
२१.९३ लाख
२०.९६ लाख
२१.८० लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-२.१५ करोड
-२.३० करोड
-२.२२ करोड
-२.७९ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू